**DENVER HEALTH AND HOSPITAL AUTHORITY**  
**BOARD MEETING**  
601 Broadway, 9th Floor, Room 927  
Thursday, January 31, 2019  
1:30 p.m. – 5:00 p.m.

**AGENDA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Item</th>
</tr>
</thead>
</table>
| 1:30 – 1:35 | I. A. Call to Order and Approval of December 20, 2018 Meeting Minutes *(Action)*  
B. Conflict of Interest Disclosure Statement  
C. Public Comment (none scheduled) |
| 1:35 – 1:40 | II. Executive Session – Attorney-Client Privilege  
A. Real-Estate Matter – Peg Burnette (5 minutes) *(Action)* |
| 1:40 – 1:55 | III. Authority Issues  
A. Medical Staff Appointments/QSSIC Comments – Dr. Lavonas (5 minutes) *(Action)*  
B. Medical Staff Executive Committee (MSEC) Update – Dr. Lavonas (10 minutes) |
| 1:55 - 2:00 | IV. Consent Calendar *(Action)*  
A. Approval of Resolution Ratifying Approval of 2019 Budget  
B. Approval of Resolution Authorizing the Fresenius Joint Venture  
C. Approval of DHMP Appointment Resolutions  
D. Approval of Resolution Regarding 550 Acoma, Inc.  
E. Approval of Resolution Designating 2019 Posting Locations |

**BACKGROUND**  
The Consent Calendar allows the Board to approve multiple routine agenda items using a single motion and vote without the need for discussion. Board members are provided with the materials for each Consent Calendar item prior to the Board meeting. Upon request, any item may be discussed and voted upon separately by the Board.

**PURPOSE**
To approve the Consent Calendar using a single motion and vote.

**ANTICIPATED OUTCOME**
Approval of the Consent Calendar.

<table>
<thead>
<tr>
<th>2:00 – 2:25</th>
<th>V. New Business</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. CEO Report – Robin Wittenstein (25 minutes) (Informational)</td>
<td></td>
</tr>
</tbody>
</table>

**BACKGROUND**
This is a recurring report and addresses topics as determined by the CEO.

**PURPOSE**
To provide an update on metric progress and operational goals.

**ANTICIPATED OUTCOME**
Board discussion and input.

| 2:25 – 2:55 | B. Patient Experience Update – Amy Friedman (30 minutes) (Informational) |

**PURPOSE**
To provide a comprehensive analysis on the current and future state of Patient Experience initiatives.

**BACKGROUND**
This topic is a focus of the organization and Board over 2019.

**ANTICIPATED ATTENDANCE**
Board discussion and input.

<table>
<thead>
<tr>
<th>2:55 – 3:05</th>
<th>-10 Minute Break -</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(Bio and Cell Phone Break)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3:05 – 3:35</th>
<th>VI. Committee and Board Member Reports</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Quality, Safety, and Service Improvement Committee (QSSIC) – Fernando Carreira, M.D. (5 minutes)</td>
<td></td>
</tr>
<tr>
<td>B. Finance, Audit, and Compliance Committee Report – Kevin Quinn (5 minutes)</td>
<td></td>
</tr>
<tr>
<td>C. Nominating and Governance Committee – Irene Aguilar, M.D. (5 minutes)</td>
<td></td>
</tr>
<tr>
<td>D. CHS Report – Susan Powers (5 minutes)</td>
<td></td>
</tr>
<tr>
<td>E. DHMP Report – Rus Heise (5 minutes)</td>
<td></td>
</tr>
<tr>
<td>F. Chair’s Report – Anne Warhover (5 minutes)</td>
<td></td>
</tr>
</tbody>
</table>

**BACKGROUND**
These committee reports are standing agenda items.

**PURPOSE**
To advise the Board as to the status of each of the committees listed above.
| 3:35 – 3:55 | VII. Executive Session – Deliberative Process and Attorney - Client Privileges  
A. Medical Staff Matter – Tom MacKenzie (10 minutes) *(Informational)*  
B. Opioid Litigation Update – Scott Hoye (10 minutes) *(Informational)* |
| --- | --- |

**BACKGROUND**  
Colorado Revised Statute §24-6-402 (4), (c), (e) and (g) allows the Board to discuss confidential matters in Executive Session; C.R.S. §24-72-204 (3) (a) (IV) and (XIII) allows the Board to review and discuss confidential materials pursuant to the deliberative process privilege; C.R.S. §24-6-402(4)(b) allows the Board to receive confidential legal advice pursuant to the attorney-client privilege; and, C.R.S. §12-36.5-104.4 provide that physician peer review matters are privileged and confidential.

**PURPOSE**  
To discuss confidential matters subject to the deliberative process and attorney-client privileges.

**ANTICIPATED OUTCOME**  
Board discussion and input regarding the above-referenced matters. Any issue requiring Board approval will be subject to a vote and related discussion in open session.